Durvalumab vs Nivolumab

Durvalumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between Durvalumab and Nivolumab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Nivolumab — 27 days.

Chemical Properties

Type: Durvalumab — Antibody; Nivolumab — Antibody.